Egetis Launches EMCITATE in the U.S. for MCT8 Deficiency

Egetis Therapeutics has announced the U.S. commercial availability of EMCITATE, also known as tiratricol, for adults and pediatric patients with MCT8 deficiency who have peripheral thyrotoxicosis.

According to Manilatimes, the launch follows U.S. Food and Drug Administration approval of EMCITATE on September 28, 2026. Egetis described EMCITATE as the first and only FDA-approved treatment for peripheral thyrotoxicosis in this patient population in the United States.

Launch centers on a rare-disease patient population

MCT8 deficiency is the focus of the EMCITATE launch, placing the product within Egetis’ stated strategy of developing and delivering therapies for patients with rare diseases. The company said commercial availability arrived ahead of anticipated timelines following FDA approval.

For pharmaceutical sales professionals, the announcement highlights a specialized launch involving a narrowly defined clinical population and both adult and pediatric patients. Product communication will need to remain aligned with the approved indication for peripheral thyrotoxicosis in patients with MCT8 deficiency.

Patient support program accompanies availability

Manilatimes reported that Egetis RareLink is the company’s dedicated patient support program for EMCITATE. Egetis said the program provides access assistance, education, and care coordination in partnership with PANTHERx Rare Pharmacy.

The combination of commercial availability and a dedicated support program underscores the operational components of rare-disease therapy launches. Egetis’ announcement identifies pharmacy partnership, patient education, care coordination, and access assistance as elements supporting the U.S. introduction of EMCITATE.

Key launch details

• Product: EMCITATE, or tiratricol
• Market: United States
• Patient population: Adults and pediatric patients with MCT8 deficiency
• Approved use cited by Egetis: Peripheral thyrotoxicosis
• Support program: Egetis RareLink, in partnership with PANTHERx Rare Pharmacy

Manilatimes published the announcement from Egetis Therapeutics on October 27, 2026.